Clinical trials: Multiple System Atrophy (MSA)
- Condition Multiple System Atrophy (MSA)
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Multiple System Atrophy (MSA)
Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)
The purpose of this expanded access program is to provide access to the investigational drug verdiperstat in patients with Multiple System Atrophy (MSA).
- Trial name
- NCT05086094
- Testing
- BHV3241, verdiperstat
- Where
- United States
- Sponsor
- Biohaven Pharmaceuticals, Inc.